Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder: Efficacy, Safety and Mechanisms of Action
The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Studies examining the efficacy, safety and mechanisms of action of agents for the treatment of attention-deficit/hyperactivity disorder (ADHD) are reviewed, with an emphasis on newer agents such as the long acting stimulants and atomoxetine. Recent studies of medications are characterized by large, rigorously diagnosed samples of children, adolescents and adults with ADHD, use of standardized rating scales and extensive safety data. These studies confirm a robust treatment effect for the Food and Drug Administration approved agents ranging from 0.7 to 1.5. The most common short term side effects to the most commonly used agents include insomnia, loss of appetite, and headaches. Despite public controversy and labeling changes to warn of extremely rare cardiovascular and psychiatric side effects, the evidence does not support the hypothesis that medication for ADHD increases risk for sudden death, mania or psychosis. A wide variety of neuroimaging techniques including electrocephalogram (EEG) power, event related potentials (ERP), functional magnetic resonance imaging (fMRI), and positron emission tomography (PET) are beginning to examine the mechanisms of action of medications for ADHD, and implicating the catecholamines and prefrontal and anterior cingulate cortices as prime sites of actions for these agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“evidence from a large body of studies showed that treatment responses from different patients are widely different in terms of the types of pharmacological treatments, dosage requirements, tolerability, response rates, and adverse-event profiles (Spencer et al., 1996; Efron et al., 1997; Pliszka, 2007; Newcorn et al., 2008; Victor et al., 2009; Wilens et al., 2011; Hodgkins et al., 2012).”
From A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD) (2019) · cites this paper as Pliszka, 2007
In the citing paper
“pharmacological treatment has limitations including unfavorable side effects for some patients [8]”
From Proof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD (2018) · cites this paper as [8]
Citations
Cites
ADHD and The Nature of Self-Control
Barkley, R. A., & Wasserstein, J. (2000) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.14.1.111 · Cited by 1,513
ADHD and the Nature of Self-Control
Hinshaw, S. P. (1998) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-199806000-00010 · Cited by 1,194
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
THE BEHAVIOR OF CHILDREN RECEIVING BENZEDRINE
Bradley, C. (1937) · American Journal of Psychiatry · doi:10.1176/ajp.94.3.577 · Cited by 1,035
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885 · cited 2×
“transporters in the striatum (Volkow et al., 1998).”
BackgroundInfluentialBush, G., Frazier, J. A., Rauch, S. L., Seidman, L. J., Whalen, P. J., Jenike, M. A., Rosen, B. R., & Biederman, J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00083-9 · Cited by 866 · cited 2×
“…comparisons of ADHD children to controls during fMRI have shown differences in fronto-striatal activity (Bush, Valera, & Seidman, 2005), particularly in the right prefrontal cortex (Rubia, Smith, Brammer, Toone, & Taylor, 2005) and anterior cingulate (Bush et al., 1999; Pliszka et al., 2006b).”
BackgroundVaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., & Gabrieli, J. D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14494 · Cited by 845 · cited 1×
“Initially, Vaidya et al. (1998) showed that MPH, relative to placebo, increased frontal activation in both children with ADHD and controls.”
BackgroundPharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830 · cited 2×
“were found in 161 studies encompassing 5 preschool, 140 school age, 7 adolescent and 9 adult RCTs (Spencer et al., 1996).”
BackgroundBarry, R. J., Clarke, A. R., & Johnstone, S. J. (2003) · Clinical Neurophysiology · doi:10.1016/s1388-2457(02)00362-0 · Cited by 819 · cited 1×
“Healthy controls produce a larger P300 wave to the oddball tones than to the common tones, but this difference is markedly reduced in children with ADHD (Barry et al., 2003).”
BackgroundAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790 · cited 7×
“Thus it is tempting to conclude that MPH increases the allocation of mental resources to a task, but Springer further studies have not borne this out.”
BackgroundInfluential
Cited by
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 671
“Moreover, current pharmacologic treatments for ADHD (e.g., methylphenidate) target dopaminergic systems, and, similar to MA, operate by blocking reuptake of dopamine and norepinephrine (Pliszka 2007).”
BackgroundSharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
“Comorbidities such as ODD, MDD, and anxiety disorders create more difficulties for ADHD diagnosis because of the similarities of these disorders with symptoms and characteristics of ADHD.”
BackgroundInfluentialA Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD)
Luo, Y., Weibman, D., Halperin, J. M., & Li, X. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00042 · Cited by 394
“Although different pharmacological treatment strategies have been applied to ADHD patients with various comorbidities, evidence from a large body of studies showed that treatment responses from different patients are widely different in terms of the types of pharmacological treatments, dosage requirements, tolerabilit…”
BackgroundAttention-Deficit/Hyperactivity Disorder and Attention Networks
Bush, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.120 · Cited by 358
“Pliszka SR (2007). Pharmacologic treatment of attention-deficit/hyperactivity”
BackgroundInfluentialAdvokat, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.03.006 · Cited by 219
Metadata
- Authors
- Pliszka, S. R.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Pliszka, Steven R.
- ORCID
- Pliszka, Steven R.
- Venue
- Neuropsychology Review
- Published
- 2007-01-23
- Volume
- 17
- Issue
- 1
- Pages
- 61-72
- ISSN
- 1040-7308 (ISSN-L)
- 1573-6660
- OpenAlex
- W2081088104
- Cited by
- 158
- References
- 99
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 9 · 2021: 3 · 2020: 10 · 2019: 11 · 2018: 2 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 12 · 2013: 5 · 2012: 12
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychology Review (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- attention deficit hyperactivity disorder, pharmacotherapy, long-acting stimulants, atomoxetine, drug efficacy, drug safety, adverse effects, sudden death risk, mechanism of action, catecholamines, prefrontal cortex, anterior cingulate cortex, neuroimaging
- MeSH terms
- Atomoxetine Hydrochloride, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Decision Trees, Humans, Propylamines, Neurotransmitter Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.